|
Biovista
www.biovista.com
|
Dr. Andreas Persidis
CEO |
Biovista delivers custom drug repositioning, drug de-risking and clinical hold solutions for the Biopharma Industry. It also develops powerful platform technologies for Life science and Biotechnology companies. |
|
Amphivena Therapeutics Inc.
amphivena.com
|
Curtis Ruegg
Ph.D. President & CEO |
Amphivena Therapeutics, Inc. is a privately held, clinical-stage, immuno-oncology company that is developing a novel platform of dual-function biologics that relieve immune suppression and drive T-cell activation and polarization to restore anti-cancer immunity in patients |
|
Biotecnol Limited
www.biotecnol.com
|
Pedro de Noronha Pissarra
Ph.D., CEO |
Biotecnol Limited is an immuno-oncology company developing immune-function activating and immuno function modulation approaches using multi-specific antibody products based on its proprietary Tribody™ and Trisoma® technologies. |
|
IamFluidics
iamfluidics.com
|
Michiel van Alst
CEO |
IamFluidics BV uniquely enables the high-throughput production of uniform microparticles. Its proprietary and disruptive platform technology is up to 1000x faster than conventional droplet microfluidics. |
|
Lumen Bioscience
www.lumen.bio
|
Brian Finrow
Co-Founder & CEO |
Lumen’s patented biologic drug platform shortens the drug development process, reduces costs and risks, and accelerates time-to-market, making us the first company to make orally delivered antibody drugs commercially viable. |
.svg)